Satya Nadella, CEO of Microsoft
Justin Solomon | CNBC
In late 2017, Microsoft invested in an experimental healthcare company called Adaptive Biotechnologies, hoping to leverage its advanced cloud technology in the life sciences while earning money as a major shareholder. [ThursdayMicrosoftseemspreparedtodoboth
Adaptive, which developed a so-called "immune medicine platform" to change the treatment of various diseases, rose to over $ 40 on its public market debut after the company had sold shares on Wednesday at $ 20 apiece , Pop means the value of Microsoft's $ 45 million investment has nearly quadrupled to $ 1
As the world's most valuable publicly traded company with a market capitalization of over $ 1 trillion, Microsoft has many opportunities to make a profit. Start-up investments are a possibility, even though the software maker was much less active than many other large technology companies like Alphabet, which has several risk groups for early and late business deals, and Salesforce, which was a big investor in Clouds software and has recently had special ones Funds launched in Canada, Japan and Australia.
Adaptive is far more at stake for Microsoft than just an investment in the largest biotech IPO to date in 2019. Microsoft's Azure unit, which ranks second behind Amazon Web Services in the cloud infrastructure market, can test its artificial intelligence tools in an industry that is likely to be highly lucrative in the years to come as more and more emerging healthcare companies rely on software cloud for heavy workloads. According to Orbis Research, the global immunology market will grow from $ 57.7 billion in 2015 to $ 74.1 billion in 2022.
Adaptive has agreed to spend at least $ 12 million on Azure, the exclusive provider of cloud services, over its seven-year IPO prospect.
"We strongly believe in the potential of this partnership with Adaptive and have made significant financial investments in the company," said Peter Lee, Microsoft Vice President for AI and Research, in a blog post when the agreement was announced. "We've also embarked on a major research and development collaboration that has brought Adaptive's scientists to work closely with our top researchers to leverage Adaptive's innovative sequencing technology and Microsoft's extensive machine learning and cloud computing capabilities To allow reading of the immune system. "
Adaptive mentions Microsoft 74 times in its prospectus. Ultimately, the two companies plan to develop a single blood test for the early detection of many diseases, including cancer and autoimmune diseases. Adaptive's competitors include Bristol-Myers Squibb, GlaxoSmithKline, Qiagen and Thermo Fisher Scientific. Sean Nolan, technical director, previously worked at Microsoft, where he led the HealthVault team, which focused on software for storing health data.
Microsoft's investment in Adaptive took months after health care was identified as a focus. In April, the company hired Gregory Moore as Corporate Vice President of Health Technology and Alliances. Prior to that, Moore led Google's cloud healthcare activities and previously worked for Geisinger healthcare.
AWS is also on the march, offering tools for genome research, as well as biotech companies, health care providers and insurers
The Chad brothers and Harlan Robins founded Adaptive in Seattle in 2009. The company had 346 employees at the end of March. Adaptive raised $ 300 million for the IPO, outperforming Cortexyme, Personalis, Prevail Therapeutics, and other biotech companies this year.
Microsoft has made further investment gains. The company inherited a stake in the software startup, Confluent, through its $ 27 billion acquisition of LinkedIn in 2016, and the value of this investment has increased dramatically since then. And earlier this week, Microsoft co-founder Bill Gates said buying a part of Facebook before the company's IPO was "a hugely successful investment"